IAM Issue 4

The making of a licensing legend

Stanford University’s Office of Technology Licensing has a string of headline
success stories to its name – from DNA gene-splicing to Cisco, Yahoo! and Sun
Microsystems. Since it was founded in 1970, it has also received US$594 million
in cumulative gross royalties. No wonder it is considered a world leader in
technology transfer. By Nigel Page


Patent predictions - facts or fictions

According to some theories we
might be at the beginning of the
next golden age of innovation.
But then again, we might be wrong

Prickly profits

Last month’s IP Investor focused on
the double standard applied to
persons who deploy intangibles like
patents for profit, as opposed to
investors who deal in hard assets.
The net-net: real estate moguls are
capitalists; aggressive exploiters of
IP are anti-competitive. The following
are insights from prominent patent
owners, managers and advisers
about the IP double standard and
what can be done to mitigate it

US antitrust enforcers focus on IP

Not only has the FTC recently
pursued an aggressive antitrust
enforcement agenda in matters
implicating IP rights, but it has
recently taken the rather
extraordinary step of trying to effect
changes to the existing substantive
laws and procedural rules in the
patent field


Opportunity knocks for IP owners in China

For many years China has had a terrible reputation among intellectual property
owners. Undoubtedly huge problems do remain but these have not deterred a
number of IP-rich foreign companies from doing business in the country, And, if
they know what they are doing, the potential upside is enormous.
By Alan Adcock

Getting it right the Australian way

The results of a recent in-depth survey of Australian companies’ attitudes to
intellectual property management have lessons that go far beyond the country.
Nowhere is this more so than in the work being done by organisations that
have identified IP rights as key drivers for growth. By Timothy Devinney
and Adam Liberman

The challenges of 2004

During 2003 there were major developments in the world’s intellectual asset
management landscape. Some more welcome than others. And it is clear that
the pace of change shows no signs of letting up. Senior figures from industry,
the law and representative organisations explain what they saw as the key
issues of the last 12 months and what we need to be looking out for in 2004.
By Joff Wild

Accurate IP valuation in multiple environments

The IP rights belonging to a well-managed, buoyant company will be worth a lot
more than those owned by a business on the verge of bankruptcy. The key to a
successful IP valuation therefore is to understand the reasons why it is being
done in the first place. By Weston Anson and Daryl Martin

Patent time bombs

In certain circumstances, patent applications can be more valuable to an
organisation than patents themselves. However, this does not happen by
accident – specific strategies have to be put in place. By Craig Opperman


Biotech companies must face up to generic rivals

In the next few years it is likely that
generic biotechnology products will begin
to hit the European and American
markets. Biotech companies will try to
slow the process down but they cannot
stop it. Which should be good news for
them and patients

Another one bites the dust

For 120 years, New York’s Pennie & Edmonds was a
specialist IP law firm with a pedigree second to none.
That did not stop it going out of business at the end of
2003. Now, with America’s general practice firms
showing little sign of scaling back their interest in
intellectual property, the pressure is on the surviving
specialist firms to keep them at bay